Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Delcath Systems has announced that the Swedish Medical Center in Englewood, Colorado, has joined the company's Phase III clinical trial for the treatment of metastatic melanoma in the liver.
Subscribe to our email newsletter
Swedish Medical Center is the ninth center to join this multi-center trial testing the company’s percutaneous hepatic perfusion system for the isolated, high-dose delivery of the anticancer agent melphalan.
Delcath and Swedish Medical Center have entered into a clinical research agreement to conduct the Phase III National Cancer Institute led study. Charles Nutting, an interventional radiologist specializing in minimally invasive cancer treatment, will serve as the principal investigator for this trial, said Delcath.
Richard Taney, president and CEO of Delcath, said: “Located immediately southwest of Denver, Colorado, Swedish Medical Center is ideally situated to allow Delcath’s percutaneous hepatic perfusion treatment to reach an important geographic region and will further advance our goal of completing enrollment of this trial in 2009.”